Targeted therapy for vulvovaginal atrophy

• Olga P. Vinogradova
• Alexander F. Shtakh
• Denis Yu. Bocharnikov
• Olga A. Biryuchkova
• Nataliya A. Mikhailova
• Mariya S. Karaseva

Abstract

The aim of the study was to determine the effectiveness of the moisturizer based on natural plant extracts and hyaluronic acid in the treatment of vulvovaginal atrophy.

Material and methods. The prospective study included data from 30 patients aged 24 to 72 years with varying degrees of vulvovaginal atrophy. All patients underwent vulvoscopy, colposcopy, vaginal pH determination, and microscopic examination of a vaginal smear for flora before and after 3 months of the gel usage. The vaginal health index, the severity of vulvovaginal atrophy symptoms using the VSQ questionnaire, and the vaginal maturation index were assessed.

Results. After a repeated study, patients using the emollient showed an improvement in their quality of life, which was assessed using the VSQ questionnaire. An objective improvement in the health of the vulvovaginal area of ​​women was also revealed according to the results of colposcopic and vulvoscopic examinations.

Conclusion. The use of the moisturizing gel Intimate Rose based on natural plant extracts and hyaluronic acid can be considered a good method of therapy and prevention of vulvovaginal atrophy. The use of this gel significantly improves the quality of life of patients with this pathology.

Keywords: vulvovaginal atrophy; genitourinary menopausal syndrome; vulvar leukoplakia; lichen sclerosus

References

1. Prilepskaya V.N. Genitourinary menopausal syndrome: the potential of estriol. Ginekologiya [Gynecology]. 2018; 20 (1): 5–8. DOI: https://doi.org/10.26442/2079-5696_20.1.5-8 (in Russian)
2. Stenyaeva N.N., Krasny A.M., Grigor’ev V.Yu. Vaginal dryness: molecular biological and sexological aspects. Effektivnaya farmakoterapiya [Effective Pharmacotherapy]. 2017; (44): 26–33. (in Russian)
3. Balan V.E., Yureneva S.V., Apolikhina I.A., et al. Urogenital disorders in the menopause. Genitourinary syndrome. In: Savel’eva (ed.). Gynecology: national guidelines. 2nd ed. Moscow: GEOTAR-Media, 2017: 275–85. (in Russian)
4. Mac Bride M.B., Rhodes D.J., Shuster L.T. Vulvovaginal atrophy. Mayo Clin Proc. 2010; 85 (1): 87–94.
5. Pestrikova T.Yu., Shveeva M.A., Yurasova E.A. Current approach to vulvo-vaginal atrophy (literature review). Dal’nevostochniy meditsinskyy zhurnal [Far Eastern Medical Journal]. 2023; (2): 100–5. DOI: https://doi.org/10.35177/1994-5191-2023-2-18 (in Russian)
6. Ayvazova D.S., Pal’chik E.A., Duyanova O.P. Vulvovaginal atrophy: modern features of etiology, clinical manifestations and therapy. In: Medical, Social and Philosophical Aspects of Human Health in Modern Society: Experience of Interdisciplinary Research. Orel, 2015: 8–11. (in Russian)
7. Balan V.E., Kovaleva L.A. Hormones and the urogenital tract. In: S.I. Rogovskaya, E.V. Lipova (eds). Cervix, Vagina, Vulva. Moscow: Mediabyuro StatusPraesens, 2016: 741–7. (in Russian)
8. Rogozhina I.E., Neyfel’d I.V., Stoliarova U.V. Correction of impaired vaginal microbiocenosis in perimenopausal women. Rossiyskiy vestnik akushera-ginecologa [Russian Bulletin of Obstetrician-Gynecologist]. 2014; 14 (5): 87–92. (in Russian)
9. Ampilogova D.M., Solopova A.G., Blinov D.V., Achkasov E.E., Petrenko D.A., Korabel’nikov D.I. Vulvovaginal atrophy: issues of treatment and rehabilitation: a review. Ginekologiya [Gynecology]. 2022; 24 (4): 240–5. DOI: https://doi.org/10.26442/20795696.2022.4.201792 (in Russian)
10. Glazunova A.V., Yureneva S.V. Prevalence of vulvovaginal atrophy and its impact on quality of life in women. The issues of terminology and the safety of local hormone therapy. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2024; (11): 29–33. (in Russian)
11. Lebedenko E.Yu., Mikhel’son A.F., Aleksanyan A.A., Rozenberg I.M., Novikova E.G., Minkina G.N., et al. Conservative approaches to correcting postmenopausal urogenital disorders. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2015; (11): 102–9. (in Russian)
12. Nappi R.E., Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014; 17 (1): 3–9.
13. Narutytė R., Žukienė G., Bartkevičienė D. Vulvovaginal atrophy following treatment for oncogynecologic pathologies: etiology, epidemiology, diagnosis, and treatment options. Medicina (Kaunas). 2024; 60 (10): 1584.
14. Shapiro M. What should guide our patient management of vulvovaginal atrophy? Climacteric. 2019; 22 (1): 38–43.
15. Rahn D.D., Carberry C., Sanses T.V., Mamik M.M., Ward R.M., Meriwether K.V., et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014; 124 (6): 1147–56.
16. Sassarini J., Perera M., Spowart K., McAllister K., Fraser J., Glasspool R., et al. Managing vulvovaginal atrophy after breast cancer. Post Reprod Health. 2018; 24 (4): 163–5.
17. Dos Santos C.C.M., Uggioni M.L.R., Colonetti T., Colonetti L., Grande A.J., Da Rosa M.I. Hyaluronic acid in postmenopause vaginal atrophy: a systematic review. J Sex Med. 2021; 18 (1): 156–66.
18. Dobrokhotova Yu.E., Il’ina I.Yu., Venediktova M.G., et al. Treatment of genitourinary menopausal syndrome in patients with gynecologic cancer. RMZh [Russian Medical Journal]. 2017; (26): 1921–5. (in Russian)
19. Yureneva S.V., Glazunova A.V., Eprikyan E.G., et al. Therapy for vulvovaginal atrophy in postmenopausal women: Clinical and pathogenetic aspects. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2017; (6): 143–50. DOI: https://doi.org/10.18565/aig.2017.6.143-50 (in Russian)
20. Cox P., Panay N. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause. Climacteric. 2023; 26 (4): 367–72.
21. Sinha A., Ewies A.A. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric. 2013; 16 (3): 305–12.
22. Jozkowski K.N., Herbenick D., Schick V., Reece M., Sanders S.A., Fortenberry J.D. Women’s perceptions about lubricant use and vaginal wetness during sexual activities. J Sex Med. 2013; 10 (2): 484–92.
23. Edwards D., Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016; 19 (2): 151–61.
24. Sarmento A.C.A., Kamilos M.F., Costa A.P.F., Vieira-Baptista P., Eleutério J. Jr, Gonçalves A.K. Use of moisturizers and lubricants for vulvovaginal atrophy. Front Reprod Health. 2021; 3: 781353.
25. Hirschberg A.L., Bitzer J., Cano A., Ceausu I., Chedraui P., Durmusoglu F., et al. Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide. Maturitas. 2021; 148: 55–61.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)